Teva Pharmaceutical Industries Ltd., of Jerusalem, completed its phase IIb migraine prevention program with positive top-line results from a study evaluating the efficacy, safety and tolerability of two doses of subcutaneous TEV-48125 for the prevention of high frequency episodic migraine (characterized by eight to 14 days of headache per month).